Common use of Safety Database Clause in Contracts

Safety Database. After the Commencement of the first human clinical trial using a Licensed Product, Immune Design or its Affiliates or its sublicensee shall maintain or have maintained a single safety database of all adverse events reported within the Territory with respect to Immune Design GLA, including those reported during the conduct of clinical trials, those reported as spontaneous, post-marketing adverse events or those resulting from a product complaint.

Safety Database. After the Commencement of the first human clinical trial using a Licensed Product, Immune Design or its Affiliates or its sublicensee shall maintain or have maintained a single safety database of all adverse events reported within the Territory with respect to Immune Design GLAGLA or SLA, including those reported during the conduct of clinical trials, those reported as spontaneous, post-marketing adverse events or those resulting from a product complaint.